NASDAQ: ADMA Class Action Notice: Berger Montague Encourages Investors to Inquire

The law firm Berger Montague PC has filed a class action lawsuit against ADMA Biologics, Inc., a biopharmaceutical company listed on NASDAQ under the ticker ADMA. The lawsuit targets investors who bought or acquired ADMA common stock during a certain period, alleging securities fraud. The firm encourages investors to inquire about their rights and potential claims related to the case. Details of the allegations or the specific period covered by the lawsuit have not been disclosed in the announcement.

This legal action could influence investor sentiment towards ADMA, especially among current and potential shareholders. While the specifics of the case are not provided, such lawsuits can sometimes lead to volatility in the company's stock price depending on the allegations and the case's progression.

It is important to note that this is a legal development and does not imply any proven wrongdoing by ADMA at this stage. Investors should consider this information as part of broader due diligence and market analysis. The impact on ADMA's stock will depend on the case's developments and market perception.